Restless legs syndrome is frequently overlooked in patients being evaluated for polyneuropathies.

Restless legs syndrome (RLS) often presents with paresthesias and dysesthesisas. We have investigated the prevalence and clinical features of RLS in a cohort of patients referred for clinical suspicion of peripheral neuropathy (PN). Sixty-four patients with sensory symptoms, and 101 age-matched controls were prospectively evaluated for RLS, PN and causes of both conditions. In the 64 patients (60 +/- 14 years), none were referred with a suspicion of RLS. Forty-one had a sensori-motor PN of which 22 had a definite RLS (54%). When excluding other causes of RLS, 8 of 41 patients had a RLS associated with a neuropathy (20%). The proportion of RLS in the healthy controls was 10%, lower than in the cohort of patients. In patients without PN, 57% had a RLS, and 55% in the whole cohort, a higher proportion than in the healthy controls (P < 0.0001). Patients with PN and RLS had more sleep disorders (P < 0.04), and legs and calves symptoms (P = 0.09) than patients with PN without RLS. Toes symptoms were more frequently observed in patients with PN but without RLS (P < 0.02). We conclude that RLS frequently presents with symptoms suggestive of peripheral neuropathy, and therefore, is often overlooked.

Walking capacities in multiple sclerosis measured by global positioning system odometer.

We used a global positioning satellite technology odometer to determine the maximum objective walking distance capacity (MOWD) of patients with multiple sclerosis (MS). The MOWD correlated with Expanded Disability Status Scale (EDSS) score (r(2) =0.41; P <0.0001), the MSWS-12 scale (r(2) =0.46; P <0.0001), time to walk 10 m (r(2) =0.51; P <0.02) and walking speed (r(2) =0.75; P <0.001). Limitation of walking capacities was measurable up to 4550 m, strikingly above the 500-m limit of the EDSS. This objective odometer is a promising tool for evaluation and follow-up of patients with MS.

Somatotopic organization of the analgesic effects of motor cortex rTMS in neuropathic pain.

BACKGROUND: Motor cortex repetitive transcranial magnetic stimulation (rTMS) was found to relieve chronic neuropathic pain, but the optimal parameters of stimulation remain to be determined, including the site of stimulation. OBJECTIVE: To determine the relationship between cortical stimulation site and pain site regarding the analgesic efficacy of rTMS of motor cortex in chronic neuropathic pain. METHODS: Thirty-six patients with unilateral chronic neuropathic pain located at the face or the hand were enrolled. Motor cortex rTMS was applied at 10 Hz over the area corresponding to the face, hand, or arm of the painful side, whatever pain location. Analgesic effects were daily assessed on visual analogue scale for the week that followed each rTMS session. RESULTS: All types of rTMS session, whatever the target, significantly relieved pain, compared with baseline. However, analgesic effects were significantly better after hand than face area stimulation in patients with facial pain and after face than hand or arm area stimulation in patients with hand pain. CONCLUSION: Repetitive transcranial magnetic stimulation was more effective for pain relief when the stimulation was applied to an area adjacent to the cortical representation of the painful zone rather than to the motor cortical area corresponding to the painful zone itself. This result contradicts the somatotopic efficacy observed for chronic epidural motor cortex stimulation with surgically implanted electrodes.